Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

113.93 -2.30 (-1.98%)
Delayed Quote Updated: 3:12 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
News headline image
Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock ↗
 
Via Benzinga
News headline image
Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk ↗
Phase 3 ROSELLA trial showed relacorilant plus chemotherapy helped patients with platinum-resistant ovarian cancer live longer without disease worsening, including those who failed prior PARP inhibitor... 
Via Stocktwits
News headline image
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Corcept (CORT) Shares Skyrocket, What You Need To Know
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 7.7% in the afternoon session after it submitted a Marketing Authorization Application to the European Medicines Agency for its... 
Via StockStory
News headline image
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 High-Flying Stocks We Approach with Caution
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
News headline image
3 Profitable Stocks That Concern Us
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Why Corcept (CORT) Shares Are Falling Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 12.3% in the morning session after reports of a significant stock sale by a top executive surfaced. The company's Chief Development... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
3 Low-Volatility Stocks We Think Twice About
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Topics Government
News headline image
Why Corcept (CORT) Stock Is Trading Up Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 2.1% in the afternoon session after the company announced a specialty pharmacy partnership with Curant Health. Corcept has selected... 
Via StockStory
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
Via Benzinga
News headline image
1 Momentum Stock with Competitive Advantages and 2 We Find Risky
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
News headline image
What Analysts Are Saying About Corcept Therapeutics Stock ↗
Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent... 
Via Benzinga
News headline image
Why Are Corcept (CORT) Shares Soaring Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 5.4% in the afternoon session after the company announced it would present new data from its pivotal Phase 3 ROSELLA trial and that... 
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Corcept (NASDAQ:CORT) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) Embodies the "Affordable Growth" Investment Strategy ↗
Discover Corcept Therapeutics (CORT), an affordable growth stock with strong revenue growth, high profitability, and a compelling valuation within the pharmaceuticals sector. 
Via Chartmill
News headline image
Corcept Therapeutics Inc (NASDAQ:CORT): A Strong Growth Stock with Solid Fundamentals and Technical Upside ↗
Corcept Therapeutics (CORT) shows strong growth, profitability, and technical momentum, making it a top pick for investors seeking high-potential stocks. 
Via Chartmill
News headline image
3 Cash-Heavy Stocks with Warning Signs
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
News headline image
CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue... 
Via StockStory
News headline image
2 Growth Stocks Set to Flourishand 1 We Avoid
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
News headline image
3 Low-Volatility Stocks That Fall Short
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Corcept (NASDAQ:CORT) Misses Q2 Sales Targets
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue... 
Via StockStory
News headline image
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.